Located in Mississauga, Canada, the 3,300ft2 facility is designed for the development and scaling of monoclonal antibodies and other mammalian-based therapeutic proteins. The facility will provide a comprehensive
This label update is based on findings from the Phase III LIBERTY-AD-HAFT trial, the first to evaluate a biologic for this patient group. Dupixent, a fully human monoclonal
The IND clearance has been received for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection. CT011 is designed to target Glypican-3
This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal include Croatia, Bulgaria, Czech Republic, Cyprus, Greece, Estonia, Latvia,
The fast track and orphan drug designations have been awarded for GFH009 (highly selective CDK9 inhibitor) to treat adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and
A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1.8 target has been clinically validated in five acute pain and one chronic pain
The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction of the first 24-hour continuous subcutaneous infusion
The deal, facilitated by Johnson & Johnson Innovation, will enable Janssen to develop cell therapies that are armed with DR-18 of Simcha. Janssen will be responsible for the
B244, which is presently being readied for international Phase III clinical trials, is a therapeutic treatment aimed at inflammatory indications such as atopic dermatitis, addressing both appearance and
The facility, which is part of the company’s strategic growth plan, aims to enhance pharmaceutical development and manufacturing offerings in Asia. This will aid in meeting the increasing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.